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Present studies have focused on a novel cyanide antidotal system, on the coencapsulation of a new sulfur donor DTO with
rhodanese within sterically stabilized liposomes. The optimal lipid composition for coencapsulation of DTO with rhodanese is the
combination of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, cholesterol, cationic lipid (DOTAP), and 1,2-dipalmitoyl-sn-
glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] ammonium salt (with molar ratios of 82.7 : 9.2 : 3.0 :
5.1). With the optimized compositions, prophylactic and therapeutic in vivo eﬃcacy studies were carried out in a mice model.
When DTO was coencapsulated with rhodanese and thiosulfate the prophylactic antidotal protection was 4.9 × LD50. Maximum
antidotal protection against cyanide intoxication (15×LD50) was achieved with coencapsulated rhodanese and DTO/thiosulfate in
combination with sodium nitrite. When applied therapeutically, 100% survival rate (6/6) was achieved at 20mg/kg cyanide doses
with the encapsulated DTO-rhodanese-thiosulfate antidotal systems with and without sodium nitrite. These data are indicating
that the appropriately formulated DTO is a promising sulfur donor for cyanide antagonism.
1. Introduction
The specific treatment of cyanide (CN) intoxication means
the use of scavengers (e.g., methemoglobin former sodium
nitrite (SN) or cobalt compounds or cyanohydrin formers,
hydroxocabalamin (Cyanokit has been approved in the US),
cobinamide [1], and/or the conversion of CN to the less toxic
thiocyanate (SCN) with exogenously administered sulfane
sulfur and sulfurtransferase enzymes [2–4]. Rhodanese (Rh)
is the best characterized multifunctional, mitochondrial
sulfurtransferase [5–8] catalyzing the transfer of a sulfane
sulfur atom from a donor molecule to cyanide. Determining
the exact role of nitrite in cyanide antagonism is not
clearly understood yet. Earlier studies were focusing on
the methemoglobin-forming eﬀect of nitrite that act as
a scavenger by forming a relative stable complex of cyanome-
themoglobin [3, 4]. Very recent studies are focusing on the
mitochondria-linked mechanism of nitrite as a nitric oxide
donor [9–11].
Extensive researches are also focusing on developing
eﬀective sulfur-containing compounds serving as sulfur do-
nors for reacting with CN with or without Rh. Thiosulfate
(TS) is the classical sulfur compound found to participate
in the enzyme reaction [3, 4, 12]. However, TS has limited
ability to reach the endogenous Rh enzyme because of a
nearly exclusive extracellular distribution [13]. Baskin et al.,
reported results on the eﬃcacy of various sulfur donors
demonstrating that altering the chemical substituent of the
longer chain sulfide modified the ability of the candidate
molecule to protect against CN toxicity [14].
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Earlier investigations were focused on administration of
free Rh and the sulfur donor (SD) directly into the blood-
stream [15–18]. Unfortunately, the free Rh enzyme was rap-
idly destroyed by the body’s immune system, which makes
the eﬃcacy of this approach quite limited. To overcome the
limitations for the circulating free Rh, micro- or nanosized
carrier systems among others sterically stabilized unilamellar
liposomes of ∼100–150 nm diameter are in the focus of
recent encapsulation eﬀorts [19]. The encapsulation of Rh
with a sulfur compound into liposomes—the so-called
coencapsulation—can oﬀer further advantages. Over stabil-
ity enhancement for Rh the coencapsulation can provide
better overall conversion of CN, since the basis component
for enzyme reaction, the sulfur donor no longer has to
penetrate the liposome membrane.
The lipid composition has a significant impact on the
encapsulation eﬃciency of the Rh and/or sulfur compound
and on the in vivo stability and antidotal eﬀect of the
carrier system [19]. Thus, optimization of the liposomal
composition is an inevitable step in the design of novel
antidotal systems.
Present work deals with a new lipophilic sulfur-contain-
ing compound, developed at the US Army Medical Research
Institute of Chemical Defense, called DTO. In order to
achieve the highest CN antidotal protection, the liposomal
encapsulation of DTO with and without Rh was examined.
The objectives of this study are (1) optimization of the
liposomal encapsulation for the new sulfur donor, DTO, with
superior sulfur donor reactivity to the present therapy TS; (2)
in vivo eﬃcacy study of the coencapsulated DTO with Rh in
combination with sodium nitrite on mice.
2. Materials and Methods
All chemicals employed were of the highest purity com-
mercially available: potassium cyanide, TS, sodium nitrite,
phosphate buﬀer components, ethanol, sodium chloride,
concentrated hydrochloric acid, and sodium hydroxide were
purchased from J. T. Baker, (Phillipsburg, NJ), formalde-
hyde and ferric nitrate were purchased from Fisher Scien-
tific (Pittsburgh, PA). The liposome components (1-palmi-
toyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1, 2-di-
oleoyl-sn-glycero-3-phosphocholine (DOPC), N-[1-(2,3-
dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride
(DOTAP), soy lecithin (LEC), cholesterol (Chol)) and
Rh were purchased from Sigma-Aldrich (St. Louis, MO),
and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-
N-[methoxy(polyethylene glycol)-2000] ammonium salt
(PEG-PE-2000) was purchased from Avanti Polar Lipids
(Alabaster, AL). Bio-Rad Protein Kit was purchased from
Bio-Rad Life Sciences Laboratories, Hercules, CA.
2.1. Animals. Male (CD-1) mice (Charles River Breeding
Laboratories, Inc., Wilmington, MA) weighing 18–20 g
were housed at 21◦C and in light-controlled rooms (12 h
light/dark, full-spectrum lighting cycle with no twilight), and
were furnished with water and 4% Rodent Chow (Teklad
HSD, Inc., CITY, WI) ad libitum. All animal procedures
were conducted in accordance with the guidelines by The
Guide for the Care and Use of Laboratory Animals (National
Academic Press, 1996), accredited by AAALAC (American
Association for the Assessment and Accreditation of Labo-
ratory Animal Care). At the termination of the experiments,
surviving animals were euthanized in accordance with the
1986 report of the AVMA Panel of Euthanasia [20].
2.2. Preparation of Sterically Stabilized Liposomes (SL) Encap-
sulating DTO (SL-DTO), or Rh (SL-Rh), or Both of Them
(SL-DTO-Rh) with and without Coencapsulated TS. POPC,
DOPC, DOTAP, LEC, PEG-PE-2000, and Chol dissolved in
ethanol were applied in various molar ratios in order to
determine the optimal lipid composition.
The liposomes were prepared by the thin-film hydration
method [21]. DTO was codissolved with the lipids. As hy-
drating solution isotonic phosphate buﬀer (pH = 7.4;
osmolarity = 290mosm) was added to the dry lipid films.
Four diﬀerent Rh concentrations (0.25mg/mL, 0.50mg/mL,
1.00mg/mL and 1.67mg/mL), and four diﬀerent DTO
concentrations (2.0; 10.0; 20.0 and 30.0mM) were investi-
gated with various liposomal lipid compositions to evaluate
the eﬀects of these parameters on encapsulation eﬃciency
for Rh and/or DTO. The total lipid concentration (lipids
and Chol together) was 10.0mg/mL. In order to obtain a
homogenous population of small unilamellar vesicles (SUV),
the multilamellar vesicles (MLV) were extruded through
polycarbonate filters (100 and 400 nm) with an extruder
(Avanti Polar Lipids Inc. Alabaster, AL). Extrusions were
repeated five times for each membrane unless otherwise
indicated.
2.3. Determination of Rhodanese Activity. The formation
of SCN from CN was measured spectrophotometrically
(Genesys 10UV, Thermo Electron Corporation, Waltham,
MA) by the method of Westley [22], with minor modifica-
tions of Petrikovics et al. [23]. One unit of Rh was defined as
the amount of enzyme that forms 1 µmol of SCN in 1min.
2.4. Sulfur Donor Reactivity. Formation of SCN from CN
with the investigated sulfur donors of TS and DTO were
determined spectrophotometrically by the method of West-
ley [22] with minor modifications of Petrikovics et al. [23].
2.5. Optimal Rh Load for SL-Rh. Four diﬀerent Rh concen-
trations (0.25mg/mL, 0.50mg/mL, 1.00mg/mL, 1.67mg/
mL) were employed with a lipid composition of POPC :
Chol : PEG-PE-2000 with and without DOTAP. Percentage of
Rh incorporation within the liposomes was determined by
the Bradford Assay [24].
2.6. Optimal Lipid Composition for Liposomal Rh Encap-
sulation. Optimal lipid composition for Rh encapsulation
was determined based on the highest enzyme activity
achieved by the same encapsulation process with various
lipid compositions. Unencapsulated Rh was separated from
SL-Rh by gel filtration on a G-100 Sephadex gel column
(0.7 cm × 10 cm; GE Healthcare BioSciences AB, Sweden).
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Measurements were carried out in isotonic phosphate buﬀer
at pH = 7.4. Rh activity for the fractions was determined as
described above.
Encapsulation eﬃciency (%)




For the spectrophotometric assays, 50 µL liposomal samples
were used. All measurements were performed at least in
triplicate.
2.7. Optimal Lipid Composition Determination for SL-DTO.
The encapsulation eﬃciency for the sulfur donor DTO was
determined by the Rh assay described above with constant
Rh concentration. When Rh concentration was constant, the
rate of formation of SCN was directly proportional to the
sulfur donor concentration.
Encapsulation eﬃciency (%)




2.8. Optimal Lipid Composition Determination for SL-Rh-
DTO. Formation of SCN by SL-Rh-DTO with various
lipid compositions was measured spectrophotometrically as
described above.
Encapsulation Eﬃciency (%)
= SCN formation by the given SL-Rh-DTO




Rh and DTO concentration
× 100.
(3)
2.9. Prophylaxis against CN in Mice Using SL-Rh, SL-DTO,
SL-DTO-TS, SL-DTO-Rh, and SL-DTO-TS-Rh in Combi-
nation with SN. Experimental animals received KCN after
pretreatment with antagonist(s) (sulfur donors and/or Rh
and/or SN). Freshly prepared SL-DTO, SL-DTO-TS, SL-
DTO-Rh, and SL-DTO-TS-Rh were administered intra-
venously (iv) by tail vein injection to mice 10min prior
to receiving CN (sc). Using 10mL/kg doses of (SL-DTO-
Rh; Table 4 experiment 5) or (SL-DTO-TS-Rh; Table 4
experiments 6 and 7) the animals received 15–20 units of
Rh. Employing 10mL/kg injections of (SL-DTO; Table 4
experiment 2) or (SL-DTO-TS; Table 4 experiments 3 and
4) the dose for DTO was 11.5mg/kg and 14.2mg/kg for the
coencapsulated TS. SN (100mg/kg; sc), was injected 45min
prior to CN (sc) injection (Table 4 experiments 4 and 7).
The animals were evaluated 24 hours after CN exposure for
mortality; surviving animals were observed for an additional
week for late-developing toxicity. No toxic eﬀects which
could be attributed to SL-DTO, SL-DTO-TS, SL-DTO-Rh,
SL-DTO-TS-Rh, TS, or SN (when administered alone or in
various combinations) were noted in any of the mice at the
doses applied. LD50 values were determined by the Dixon
up and down method [25], using 8–18 mice for each LD50
determination. The LD50 values were given for three or
more experiments. The “antidotal potency ratio” (APR) is
expressed as a ratio of LD50(mean) of CN with antagonists and
LD50(mean) of CN without antagonists.
2.10. Therapeutic Protection against CN in Mice Using SL-
DTO-TS and SL-DTO-TS-Rh in Combination with SN.
Animals received antidotes administered intravenously one
min after CN injection (sc). Doses of antidotes were the
same as described above for the prophylactic experiments.
The animals were evaluated 24 hours after CN exposure for
Table 1: Comparison of in vitro sulfur donor reactivity of TS and
DTO determined with free Rh.
Rate of CN conversion (mmol SCN/min) Ratio
TS DTO DTO/TS
0.2 3.0 15.0
mortality. Results are given as % survival (animals alive/
animals total). Total numbers of animals were 6 for each ther-
apeutic experiment for each antidotal system.
3. Results and Discussion
These studies focused on the encapsulation optimization for
new sulfur donor DTO when encapsulated with Rh and/or
TS within sterically stabilized liposomes. The in vitro sulfur
donor reactivity comparison shows that DTO reacts 15-
times faster with CN at constant Rh concentration than TS
(Table 1). Encapsulation eﬃciencies for both Rh and DTO
were optimized as a function of Rh-load, DTO-load, and
lipid composition.
When encapsulating Rh alone, small amount of the
cationic lipid DOTAP proved to be beneficial to enhance
encapsulation eﬃciency (Table 2). The optimum Rh concen-
tration within the liposomes was 0.25mg/mL (Table 2).
For the encapsulation of DTO with a concentration of
2mM, six diﬀerent liposomal compositions were examined
to rule out the role of lipid composition (Table 3). Each
contained PEG-PE-2000 in 5.1mol%, lipid-to-Chol ratio
was 9 to 1. Also, the cationic lipid, DOTAP in 3.0mol%,
was utilized to influence the charge of the liposomal surface
in hopes that a positively charged surface would provide
increased aﬃnity for DTO. On the basis of the results
it can be concluded that the presence of DOTAP leads
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% of Rh incorporation determined
by Bradford
POPC : Chol : PEG-PE-2000 = 56.9 : 38: 5.1 1.00 16.6
POPC : Chol : PEG-PE-2000 = 56.9 : 38: 5.1 0.25 26.9
POPC : Chol : PEG-PE-2000 : DOTAP = 82.7 : 9.2 : 5.1 : 3.0 1.67 18.2
POPC : Chol : PEG-PE-2000 : DOTAP = 82.7 : 9.2 : 5.1 : 3.0 0.50 55.8
POPC : Chol : PEG-PE-2000 : DOTAP = 82.7 : 9.2 : 5.1 : 3.0 0.25 74.0
POPC : Chol : PEG-PE-2000 : DOTAP = 82.7 : 9.2 : 5.1 : 3.0 1.00 52.9
Table 3: Encapsulation eﬃciencies for DTO in various liposome compositions with and without DOTAP. DTO concentration was 2.0mM.
Total lipid concentration was 10.0mg/mL.
Liposomal composition (mol%) Encapsulation eﬃciency (%) with various lipid components
Lipid Chol PEG-PE-2000 DOTAP POPC DOPC LEC
82.71 9.19 5.1 3.0 78.4 ± 2.3 81.7 ± 3.1 64.3 ± 3.0
85.41 9.49 5.1 — 60.7 ± 3.0 63.8 ± 1.2 61.6 ± 1.5
to significant (P < 0.05) higher encapsulation eﬃciency
with DOPC and POPC as main lipid component. LEC
liposomes demonstrated the least encapsulation eﬃciency
for DTO, and DOTAP appeared to provide little to no
enhancement (Table 3). The role of DOTAP in enhancing the
encapsulation eﬃciency can be explained with electrostatic
interactions between DOTAP and DTO at the pH value
examined (pH = 7.4). Early experiments with the 60 : 40
ratio of dipalmitoyl-phosphatidylcholine (DPPC) to Chol
composition provided very low encapsulation eﬃciency for
encapsulation of DTO (data not shown here). As DTO
is a lipophilic sulfur donor, it can be expected that it is
localized in the liposomal bilayer, more or less immersed
in it. The saturated bonds of DPPC providing an ordered,
relative rigid structure may inhibit the immersion of DTO
in the liposomal membrane. Contrarily, POPC and DOPC
possessing double bonds and as a consequent of it a less
ordered and more fluid membrane structure can promote
the encapsulation of DTO. Thus, instead of DPPC, DOPC,
or POPC were used for liposome preparation and ratios were
adjusted to 90 : 10 lipid to Chol. The results shown in Table 3
indicate that DOPC liposomes containing 3mol% DOTAP
provided the highest encapsulation eﬃciency at 81.7± 3.1%.
POPC liposomes with 3%DOTAP were close behind with an
encapsulation eﬃciency of 78.4 ± 2.3%. However, there was
no significant diﬀerence between encapsulation eﬃciencies
with DOPC and POPC.
The liposome compositions including DOTAP were used
in further experiments due to the increase in encapsulation
eﬃciency achieved by these films. The eﬀect on encap-
sulation eﬃciency by the increase in DTO concentration
was evaluated for DOPC and POPC containing liposome
compositions with both sets of liposomes containing 3%
DOTAP. In order to evaluate the role of DTO concentration
on the encapsulation eﬃciency each set’s films were prepared
with DTO concentrations of 10mM, 20mM, and 30mM.
The encapsulation eﬃciency remained high for each lipo-
some formulation containing 3% DOTAP for each applied
DTO concentrations of 10mM, 20mM, and 30mM. The
encapsulation eﬃciencies of DTO for POPC samples were
69.7 ± 2.3%, 82.8 ± 7.1%, 79.2 ± 8.1%, while for the DOPC
samples DTO encapsulation eﬃciencies of 74.2 ± 2.0%,
86.2 ± 3.9%, and 89.9 ± 4.2% were determined, for 10mM,
20mM, and 30mM DTO concentrations, respectively. For a
given DTO concentration there was no significant diﬀerence
between the encapsulation eﬃciency values for DOPC or
POPC liposomes (P > 0.05).
3.1. Reevaluation of Rhodanese Encapsulation. The optimal
liposome composition for the encapsulation of Rh was
determined in earlier experiments to be the 60 : 40 ratio
of POPC to Chol [19]. However, the prior experiments
did not evaluate the DOPC or the cationic lipid DOTAP.
Furthermore, Rh was added either in isotonic HEPES
buﬀer (pH = 7.4–7.7) or in 5% (w/w) aqueous solution
of glucose (GLU; pH = 4.2–7.8) to the dry lipid films.
For the purpose of coencapsulating DTO with Rh, the Rh
encapsulation eﬃciency must be determined for the same
lipid compositions and in the same hydrating systems as
in the case of DTO. The optimal liposome composition
for Rh encapsulation was the 90 : 10 ratio of POPC to
Chol with the use of DOTAP. Also, the 3.0mol% DOTAP
again increased the encapsulation eﬃciency for most of the
diﬀerent liposomal compositions (Table 2).
3.2. Coencapsulation of DTO and Rhodanese. For the coen-
capsulation of DTO and Rh, the combination of POPC,
Chol, PEG-PE-2000, and DOTAP (with molar ratios of
82.7 : 9.2 : 5.1 : 3.0) was chosen as the most adequate lipo-
some composition. The mentioned composition of sterically
stabilized, positively charged liposomes performed the best
in the coencapsulation, with a coencapsulation eﬃciency for
Rh and DTO of 88.6± 17.1% (with a Rh load of 0.25mg/mL
and a DTO concentration of 30mM). As the coencapsulation
eﬃciency was determined on the basis of SCN formation
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Table 4: Prophylactic protection by various cyanide antidotal combinations. APR denotes antidotal potency ratio, which can be calculated
as the ratio of the average LD50 of CN with and without antagonists.
Exp no. Treatment LD50 (mg/kg; mean; range) APR
1 Control 7.8 (4.6–13.1) 1
2 (SL-DTO) (iv) + CN (sc) 17.3 (9.8–30.7) 2.2
3 (SL-DTO-TS) (iv) + CN (sc) 38.0 (21.5–67.3) 4.8
4 (SL-DTO-TS) (iv) + SN (ip) + CN (sc) 52.7 (29.7–93.2) 6.7
5 (SL-DTO-Rh) (iv) + CN (sc) 30.7 (14.6–64.0) 3.9
6 (SL-DTO-TS-Rh) (iv) + CN (sc) 38.0 (22.6–64.2) 4.9
7 (SL-DTO-TS-Rh) (iv)+ SN (ip) + CN (sc) 120.0 (68.2–213.0) 15.3
Table 5: Relative prophylactic antidotal potency ratios (RAPRs) to
express enhancing eﬀects by Rh, SN, and coencapsulated TS.
Enhancing eﬀects by Rh RAPR
Comparison of exps 5 and 2 3.9/2.2 = 1.8
Comparison of exps 7 and 4 15.3/6.7 = 2.3
Enhancing eﬀects by SN RAPR
Comparison of exps 4 and 3 6.7/4.8 = 1.4
Comparison of exps 7 and 6 15.3/4.9 = 3.1
Enhancement by coencapsulated TS RAPR
Comparison of exps 3 and 2 4.8/2.2 = 2.1
Comparison of exps 6 and 5 4.9/3.9 = 1.3
by SL-Rh-DTO; the given value represents the combined
eﬀect of Rh and DTO in CN conversion. For the sake of
comparison, encapsulation eﬃciency for the coencapsulated
Rh alone—with 0.25mg/mL concentration—was 74%, while
for DTO alone—with 10mM DTO load—was 57.7 ± 8.1%.
Increasing the concentration of DTO produced similar
encapsulation eﬃciencies, than in case of 10mM. With DTO
loads of 20mM and 30mM for the coencapsulated DTO
encapsulation eﬃciencies of 55.6 ± 4.0% and 61.6 ± 17.6%
were measured, respectively. The conversion of CN to SCN
by the coencapsulation of 10mM, 20mM, and 30mM DTO
with Rh also proved to remain linear with an R2 value of
0.9930. The ability to co-encapsulate DTO, or any other
sulfur donor molecule with Rh should provide better overall
conversion of CN, since the sulfur donor no longer has to
penetrate the liposome membrane.
3.3. In Vivo Eﬃcacy Testing. In vivo evaluation of the opti-
mized liposomal preparations made from DTO/(DTO +
TS) and/or Rh were tested as cyanide antidotes on a mice
model. Based on the above optimization eﬀorts, for further
in vivo evaluations we employed 3% DOTAP; 0.25mg/mL
Rh load, 30mM DTO load with the lipid composition of
POPC : Chol : PEG-PE-2000 : DOTAP = 82.7 : 9.2 : 5.1 : 3.0.
The in vivo eﬃcacy was expressed as antidotal potency ratio
(APR).
The in vivo prophylactic treatment results with Rh and
DTO/TS encapsulated within the optimized liposomal for-
mulations are shown in Table 4.
SL-DTO alone provided a protection with an APR of
2.2. (Table 4 experiment 2). This protection was enhanced
Table 6: Therapeutic protection by various CN antidotal combina-





1 15 (SL-DTO-TS-Rh) 6/6 (100%)
2 15 (SL-DTO-TS) + SN 6/6 (100%)
3 15 (SL-DTO-TS-Rh) + SN 6/6 (100%)
4 20 (SL-DTO-TS) + SN 4/6 (67%)
5 20 (SL-DTO-TS-Rh) 6/6 (100%)
6 20 (SL-DTO-TS) 3/6 (50%)
7 20 (SL-DTO-TS-Rh) + SN 6/6 (100%)
(APR = 4.8) when TS was coencapsulated with DTO in a
molar ratio of 1 : 1 (Table 4 experiment 3). Coencapsulation
of TS with DTO is also believed to provide protection
against product inhibition by sulphite (Zottolla, personal
communication). As it was expected, SN further enhanced
the protection with the APR of 6.7. (Table 4 experiment 4).
When DTOwas coencapsulated with Rh (Table 4 experiment
5), the APR was 3.9. When DTO was coencapsulated with
TS and Rh, (SL-DTO-Rh) the APR was enhanced to 4.9
(Table 4 experiment 6). The highest protection (APR = 15.3)
was achieved with the combination of (SL-DTO-TS-Rh) and
SN (Table 4 experiment 7). Expressing the relative antidotal
potency ratios (RAPR) better indicates the diﬀerences in
protection with two antidotal systems (Table 5). Comparing
experiment 2 and 3 (RAPR = 2.2) represents the eﬀects of TS
coencapsulation with DTO. When comparing experiments 3
and 4 (RAPR = 1.4) or experiments 6 and 7 (RAPR = 3.1)
the enhancement eﬀects reached by SN are represented. The
significant enhancement by Rh is expressed when comparing
experiments 2 and 5 (RAPR = 1.8) and experiments 4 and 7
(RAPR = 2.3) confirming earlier studies with other types of
encapsulation formulations for Rh [23, 26, 27].
Table 6 shows the therapeutic antidotal protection with
the (SL-DTO-TS-Rh) combinations with and without SN.
At approximately 2 LD50 dose of KCN (15mg/kg), all the 6
animals survived in each experiment (Table 6 experiments
1, 2, and 3). However, when the KCN dose was enhanced
(20mg/kg, approximately 3 LD50) the survival rate with
(SL-DTO-TS) + SN was 67% (Table 6 experiment 4), while
with (SL-DTO-TS) without SN provided a 50% survival
rate (Table 6 experiment 6). However the (SL-DTO-TS-Rh)
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antidotal system with and without SN also provided a 100%
therapeutic protection (Table 6 experiments 5 and 7).
4. Conclusions
The present experiments and results are confirming that the
approach of utilizing externally administered, encapsulated,
metabolizing rhodanese may have broad implications in
cyanide antidotal therapy. The application of this approach
has been successfully tested in animal models. In summary,
these studies are describing the prophylactic and ther-
apeutic in vivo eﬃcacy of the encapsulated Rh and the new,
reactive sulfur donor DTO. Optimization eﬀorts were at-
tempted for the liposomal lipid compositions, Rh-load, and
coencapsulation of two sulfur donors (TS and DTO) and
Rh to enhance the encapsulation eﬃciency for the given
components. Optimization of the carrier systems is always
a major part of these types of research eﬀorts. Considering
the high lipophilicity of DTO, for further in vivo applications
other introduction routes (e.g., intramuscular) with further
formulation optimizations are recommended.
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